These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 18574040)

  • 1. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
    Sadler JE
    Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic thrombocytopenic purpura: a moving target.
    Sadler JE
    Hematology Am Soc Hematol Educ Program; 2006; ():415-20. PubMed ID: 17124092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S; Fujimura Y
    Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.
    Tsai HM
    Kidney Int Suppl; 2009 Feb; (112):S11-4. PubMed ID: 19180123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
    Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
    Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thrombotic-thrombocytopenic purpura].
    Hellmann M; Hallek M; Scharrer I
    Internist (Berl); 2010 Sep; 51(9):1136, 1138-44. PubMed ID: 20689903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current insight into thrombotic thrombocytopenic purpura.
    Verbeke L; Delforge M; Dierickx D
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
    Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
    J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
    Coppo P; Veyradier A
    Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.
    Tsai HM
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):609-32, v. PubMed ID: 17666281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent therapeutic strategy for thrombotic thrombocytopenic purpura].
    Fujimura Y; Matsumoto M; Isonishi A; Yagi H; Kokame K; Miyata T
    Rinsho Ketsueki; 2014 Jan; 55(1):93-104. PubMed ID: 24492042
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombotic thrombocytopenic purpura-what is new?
    Shah N; Sarode R
    J Clin Apher; 2013 Feb; 28(1):30-5. PubMed ID: 23420593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
    Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
    Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
    Zheng X; Pallera AM; Goodnough LT; Sadler JE; Blinder MA
    Ann Intern Med; 2003 Jan; 138(2):105-8. PubMed ID: 12529092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura.
    Foley SR; Webert K; Arnold DM; Rock GA; Clark WF; Barth D; Sutton DM;
    Kidney Int Suppl; 2009 Feb; (112):S55-8. PubMed ID: 19180138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of thrombotic thrombocytopenic purpura.
    Tsai HM
    Int J Hematol; 2010 Jan; 91(1):1-19. PubMed ID: 20058209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for thrombotic thrombocytopenic purpura.
    Cataland SR; Wu HM
    Curr Opin Hematol; 2005 Sep; 12(5):359-63. PubMed ID: 16093780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
    Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
    Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency.
    Yagi H; Matsumoto M; Fujimura Y
    Presse Med; 2012 Mar; 41(3 Pt 2):e137-55. PubMed ID: 22264931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.